Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million

Plans Underway to Expand Use to Pediatrics, Patient Redosing and European Approval Meg Flippin, Benzinga Staff Writer GERMANTOWN, MD / ACCESS Newswire / April 7, 2026 / Precigen Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company developing precision medicines to improve the quality of life for people suffering from recurrent respiratory papillomatosis (RRP) and other diseases, is making progress on that front, announcing it has seen "robust uptake" in usage of PAPZIMEOS (zopapogene imadenovec-drba), since launching the immunotherapy in August 2025. What's more, the company announced that the Centers for Medicare & Medicaid Services (CMS) assigned J-code J3404 to the therapy effective April 1, 2026, which will streamline reimbursement and broaden access to the treatment.

Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31

GERMANTOWN, Md., March 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO, and Phil Tennant, Chief Commercial Officer, of Precigen, will participate in a virtual fireside chat with H.C.

Precigen Reports Full Year 2025 Financial Results and Business Updates

Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS™ (zopapogene imadenovec-drba), the first-and-only FDA-approved treatment for adults with RRP, in August 2025 PAPZIMEOS generated $3.4 million in net product revenue in the fourth quarter of 2025, reflecting the first partial quarter of US commercial sales as payer policies came into effect; the US launch continues to build strong momentum, with a significant increase in demand in the first quarter of 2026 The Centers for Medicare and Medicaid Services has assigned a permanent J-code, J3404, to PAPZIMEOS, effective April 1, 2026, streamlining the claims process and facilitating broader patient access Marketing Authorization Application for PAPZIMEOS for the treatment of adults with RRP validated by the European Medicines Agency and is under review Open-label redosing study initiated to evaluate retreatment efficacy of zopapogene imadenovec in adults with RRP Expert consensus paper sponsored and published by the Recurrent Respiratory Papillomatosis Foundation and authored by 16 leading physicians in the field of RRP recommended PAPZIMEOS as the new standard of care first-line treatment for adults with RRP in the US Cash, cash equivalents, and investments totaled $100.4 million as of December 31, 2025, which is expected to fund the Company's operations to cash flow break-even Conference call scheduled for 4:30 PM ET today to discuss full year 2025 financial results and provide further substantive updates on commercial progress for the first quarter of 2026 GERMANTOWN, Md., March 25, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced full year 2025 financial results and business updates.

New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis

Independent, expert-led consensus paper, sponsored by the Recurrent Respiratory Papillomatosis Foundation, reflects the recommendation of 16 leading physicians in the field of RRP Consensus paper recommends PAPZIMEOS as the new standard of care  first-line treatment for adults with RRP GERMANTOWN, Md., Jan. 20, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the publication of a new expert consensus paper sponsored by the Recurrent Respiratory Papillomatosis Foundation (RRPF) and authored by 16 leading physicians in the field of recurrent respiratory papillomatosis (RRP) has been published in The Laryngoscope, one of the field's most respected peer-reviewed journals.